Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focused on developing therapies for degenerative retinal diseases, has scheduled a webcast for May 14, 2025, at 4:30 p.m. Eastern Time. During the webcast, the company will discuss its financial results for the first quarter ended March 31, 2025, and provide a business update.
The webcast will be accessible through the company's investor relations website, and a replay will be available for approximately 90 days following the event. Belite Bio specializes in developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs.
Belite Bio (NASDAQ: BLTE), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie per malattie degenerative della retina, ha programmato una webcast per il 14 maggio 2025 alle 16:30 ora orientale. Durante la trasmissione, l'azienda discuter脿 i risultati finanziari del primo trimestre terminato il 31 marzo 2025 e fornir脿 un aggiornamento sulle attivit脿 aziendali.
La webcast sar脿 accessibile tramite il sito web delle relazioni con gli investitori dell'azienda e sar脿 disponibile una registrazione per circa 90 giorni dopo l'evento. Belite Bio si concentra nello sviluppo di nuovi trattamenti per malattie degenerative della retina con importanti bisogni medici insoddisfatti.
Belite Bio (NASDAQ: BLTE), una empresa biofarmac茅utica en etapa cl铆nica enfocada en desarrollar terapias para enfermedades degenerativas de la retina, ha programado una transmisi贸n en l铆nea para el 14 de mayo de 2025 a las 4:30 p.m. hora del Este. Durante la transmisi贸n, la compa帽铆a discutir谩 sus resultados financieros del primer trimestre finalizado el 31 de marzo de 2025 y ofrecer谩 una actualizaci贸n del negocio.
La transmisi贸n estar谩 disponible a trav茅s del sitio web de relaciones con inversionistas de la empresa, y una repetici贸n estar谩 accesible aproximadamente por 90 d铆as despu茅s del evento. Belite Bio se especializa en el desarrollo de terapias novedosas para enfermedades degenerativas de la retina con necesidades m茅dicas significativas no cubiertas.
Belite Bio (NASDAQ: BLTE)電� 韲错枆靹� 毵濍 歆堩櫂 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 5鞗� 14鞚� 鞓ろ泟 4鞁� 30攵�(霃欕秬 響滌鞁�)鞐� 鞗轨簮鞀ろ姼毳� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 鞗轨簮鞀ろ姼鞐愳劀電� 2025雲� 3鞗� 31鞚茧 膦呺霅� 1攵勱赴 鞛 鞁れ爜瓿� 靷梾 順勴櫓鞐� 雽�頃� 雲检潣頃� 鞓堨爼鞛呺媹雼�.
鞗轨簮鞀ろ姼電� 須岇偓鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞝戩啀頃� 靾� 鞛堨溂氅�, 頄夓偓 頉� 鞎� 90鞚� 霃欖晥 雼れ嫓氤搓赴 靹滊箘鞀り皜 鞝滉车霅╇媹雼�. Belite Bio電� 欷戨寑頃� 氙胳订臁� 鞚橂 靾橃殧臧� 鞛堧姅 韲错枆靹� 毵濍 歆堩櫂鞐� 雽�頃� 順侅嫚鞝侅澑 旃橂鞝� 臧滊皽鞐� 韸鬼檾霅橃柎 鞛堨姷雼堧嫟.
Belite Bio (NASDAQ : BLTE), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans le d茅veloppement de th茅rapies pour les maladies d茅g茅n茅ratives de la r茅tine, a programm茅 une webdiffusion pour le 14 mai 2025 脿 16h30 heure de l'Est. Lors de cette webdiffusion, la soci茅t茅 discutera de ses r茅sultats financiers pour le premier trimestre clos le 31 mars 2025 et fournira une mise 脿 jour commerciale.
La webdiffusion sera accessible via le site web des relations investisseurs de la soci茅t茅, et un replay sera disponible pendant environ 90 jours apr猫s l'茅v茅nement. Belite Bio se sp茅cialise dans le d茅veloppement de nouveaux traitements pour les maladies d茅g茅n茅ratives de la r茅tine pr茅sentant des besoins m茅dicaux importants non satisfaits.
Belite Bio (NASDAQ: BLTE), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Therapien f眉r degenerative Netzhauterkrankungen spezialisiert hat, hat eine Webcast f眉r den 14. Mai 2025 um 16:30 Uhr Eastern Time angek眉ndigt. W盲hrend des Webcasts wird das Unternehmen die Finanzergebnisse f眉r das am 31. M盲rz 2025 beendete erste Quartal vorstellen und ein Gesch盲ftsupdate geben.
Der Webcast ist 眉ber die Investor-Relations-Website des Unternehmens zug盲nglich, und eine Aufzeichnung wird etwa 90 Tage nach der Veranstaltung verf眉gbar sein. Belite Bio spezialisiert sich auf die Entwicklung neuartiger Therapeutika f眉r degenerative Netzhauterkrankungen mit erheblichem ungedecktem medizinischem Bedarf.
- None.
- None.
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to discuss the Company鈥檚 financial results and provide a business update for the first quarter ended March 31, 2025.
Webcast Information
Date: Wednesday, May 14, 2025
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link:
Webcast Link Instructions
You can join the live webcast by visiting the link above or the 鈥淧resentations & Events鈥� section of the Company鈥檚 Investor Relations website at聽. A replay will be available for approximately 90 days after the event.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite鈥檚 lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on聽,听,听,听聽or visit us at聽.
Media and Investor Relations Contact:
Jennifer Wu
Julie Fallon
FAQ
When is Belite Bio (BLTE) hosting its Q1 2025 earnings webcast?
How can I access Belite Bio's Q1 2025 earnings webcast?
How long will the replay of Belite Bio's Q1 2025 earnings webcast be available?
What is Belite Bio's main business focus?
